Takeda Pharmaceutical Company Limited (TKPHF)
OTCMKTS
· Delayed Price · Currency is USD
25.55
0.00 (0.00%)
Nov 21, 2024, 4:00 PM EST
TKPHF Revenue
Takeda Pharmaceutical Company had revenue of 1.18T JPY in the quarter ending September 30, 2024, with 12.75% growth. This brings the company's revenue in the last twelve months to 4.55T, up 9.43% year-over-year. In the fiscal year ending March 31, 2024, Takeda Pharmaceutical Company had annual revenue of 4.26T with 5.87% growth.
Revenue (ttm)
4,546.08B JPY
Revenue Growth
+9.43%
P/S Ratio
n/a
Revenue / Employee
92.25M JPY
Employees
49,281
Market Cap
42.27B USD
Revenue Chart
* This company reports financials in JPY.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2024 | 4,263.76B | 236.28B | 5.87% |
Mar 31, 2023 | 4,027.48B | 458.47B | 12.85% |
Mar 31, 2022 | 3,569.01B | 371.19B | 11.61% |
Mar 31, 2021 | 3,197.81B | -93.38B | -2.84% |
Mar 31, 2020 | 3,291.19B | 1,193.96B | 56.93% |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Mar 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Sandoz Group AG | 10.11B |
Telix Pharmaceuticals Limited | 430.80M |
Elekta AB (publ) | 1.69B |
Ryman Healthcare Limited | 411.39M |
Verano Holdings Corp. | 897.57M |
Vireo Growth Inc. | 98.53M |
Medexus Pharmaceuticals Inc. | 104.76M |
Takeda Pharmaceutical Company News
- 15 days ago - Takeda Pharmaceutical Co Ltd (TAK) Shares Gap Down to $13.745 on Nov 6 - GuruFocus
- 21 days ago - Takeda Pharmaceutical Company Limited 2025 Q2 - Results - Earnings Call Presentation - Seeking Alpha
- 21 days ago - Takeda Pharmaceutical Company Limited (TAK) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 22 days ago - Takeda Raises Full-Year Outlook on Cost Cuts, Restructuring Plan - BNN Bloomberg
- 22 days ago - Japan's Takeda returns to Q2 profit as drugmaker recovers from impairments - Reuters
- 22 days ago - Takeda Pharmaceutical reports H1 results, revises FY forecast - Seeking Alpha
- 22 days ago - Takeda Announces Strong First Half FY2024 Results and Raises Full Year Outlook - Business Wire
- 22 days ago - Takeda Pharmaceutical FQ2 Earnings Preview - Seeking Alpha